Overview

HDDO-1756 Bio Equivalence Study

Status:
Completed

Trial end date:
2020-07-27

Target enrollment:

Participant gender:

Summary

For healthy adult volunteers, safety and pharmacokinetic properties are compared between the two formulations in the case of HDDO-1756 alone administration and HDDO-17561/HDDO-17562 combined administration.

Phase:

Phase 1

Details

Lead Sponsor:

Hyundai Pharmaceutical Co., LTD.